Free Trial
→ The Death of the Nasdaq? (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:DXR

Daxor Q2 2025 Earnings Report

Daxor logo
$9.88 +0.22 (+2.23%)
As of 12:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Daxor EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Daxor Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Daxor Announcement Details

Quarter
Q2 2025
Date
3/2/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Daxor Earnings Headlines

Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/daxor-leverages-medaxiom-cv-transforum-spring-26-to-accelerate-commercial-adoption-of-blood-volume-analysis-1036071514
Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282545/0/en/daxor-leverages-medaxiom-cv-transforum-spring-26-to-accelerate-commercial-adoption-of-blood-volume-analysis.html
The chokepoint supplier behind SpaceX's $1.75 trillion empire
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.tc pixel
May 8 at 1:00 AM  |  Behind the Markets (Ad)
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
April 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/08/3270056/0/en/daxor-expands-customer-footprint-with-new-bva-program-at-high-volume-ohio-cardiology-center.html
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
March 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/daxor-blood-volume-analysis-metric-120000876.html
Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
March 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/26/3262937/0/en/daxor-s-blood-volume-analysis-metric-validated-as-uniquely-accurate-versus-capillary-leak-indexes-in-new-clinical-data-presented-at-sccm-2026.html
See More Daxor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daxor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daxor and other key companies, straight to your email.

About Daxor

Daxor (NASDAQ:DXR) is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. The company offers training and technical support to hospital laboratories and specialty clinics, ensuring that staff are properly instructed in isotope handling, system operation and result interpretation. Through ongoing research collaborations, Daxor continuously evaluates new protocols and software enhancements to improve diagnostic performance and workflow efficiency.

Headquartered in New York, Daxor serves healthcare providers in North America and has established distribution partnerships in Europe, Asia‐Pacific and select emerging markets. Its solutions are used by major university medical centers, community hospitals and research institutions to inform decisions on blood transfusion, fluid management and therapeutic intervention. The company’s management team brings decades of experience in medical technology commercialization, regulatory affairs and laboratory operations, positioning Daxor to expand its global footprint and address evolving needs in patient blood management.

View Daxor Profile
Earnings Tools